Compare Northrop Grumman Corporation (NOC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Northrop Grumman Corporation trades at $480.72 (market cap $68.83B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Northrop Grumman Corporation is far larger — about 6.8× State Street SPDR S&P Biotech ETF's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NOC | XBI | |
|---|---|---|
Market Cap | $68.83B | $10.11B |
Volume | 1,081,989 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $768.02 | $169.55 |
52-Week Low | $473.46 | $104.99 |
Typical Hold Time | 81 Days | 38 Days |
Enterprise Value | $82.81B | — |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $484.48, up 2.33% today, but technical indicators signal a bearish trend with the stock below key moving averages. Fundamentally, the company shows strength with a P/E of 15.4, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a mixed environment, including a significant contract loss to Boeing but sustained demand from defense budgets and a record backlog supporting future revenue.
The outlook remains positive due to strong fundamentals and analyst consensus, with a price target of $600.62 implying substantial upside. Key risks include competitive pressures from recent contract losses and dependence on government spending, but the company's financial health and dividend payments provide stability for investors.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
